Is the Future of Gene Editing Finally Here?
Developing new cell therapies is a long and difficult process. Scientists face many challenges, including the precision and safety of gene editing tools. What if there was a faster, more reliable way to bring these treatments to patients? REPROCELL’s latest announcement may have the answer. On January 28, 2026, REPROCELL launched StemEdit, a new clinical […]
REPROCELL USA Secures Funding from Maryland Stem Cell Research Fund (MSCRF)
REPROCELL USA, a leader in the production of clinically relevant human induced pluripotent stem cells (hiPSCs), has announced the receipt of funding from the Maryland Stem Cell Research Fund (MSCRF) for both of its proposals submitted in the January 2024 grant cycle. These grants will significantly enhance the company’s capabilities in cell therapy and therapeutic […]
REPROCELL USA Launches Advanced GMP Facility for Stem Cell Manufacturing
REPROCELL USA has marked a significant milestone with the inauguration of its state-of-the-art GMP manufacturing facility dedicated to producing high-quality stem cells. This facility, located in Beltsville, Maryland, was officially opened on May 15, 2024, by Mr. Kevin Anderson, Secretary of the Department of Commerce, State of Maryland. The new facility is designed to manufacture […]
REPROCELL and Gameto Collaborate to Enhance Assisted Fertility Using iPSCs
REPROCELL Inc. has recently announced a licensing agreement with Gameto Inc., a female-led biotech firm dedicated to transforming women’s healthcare. This agreement grants Gameto a non-exclusive right to utilize REPROCELL’s StemRNA™ Clinical Seed iPSCs. Gameto intends to leverage this clinical-grade iPSC line for the development and commercialization of its innovative program, Fertilo, which aims to […]